AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04164277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Preschooler Learning.
Description: Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
Study NCT04164277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-based Preschooler Component.
Description: Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat \& Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity.
Study NCT05308121 — intervention group
Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of Achilles tendon
Description: The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from two different points with the ankle in the neutral position.
Study NCT05590273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CALM Therapy
Description: The CALM intervention includes 3 to 6 individual therapy Zoom teletherapy sessions, each approximately 50-60 minutes in length biweekly, delivered over 3 months. Participants (caregivers) will be asked to complete self-report surveys of behavioral and psychological variables surveys at the following timepoints:~Within one week before initiating the CALM intervention therapy (baseline) and immediately after the program (post-intervention)~In addition, after each intervention session, participants will complete a brief post-session survey to assess acceptability of CALM session components.~Lastly, participants will complete an exit interview immediately following the end of the intervention.
Study NCT05308121 — intervention group
Intervention type: OTHER
Intervention: Evaluation of foot characteristics
Description: The mobility of foot, morphological changes of foot and foot posture will be evaluated
Study NCT04749017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product consumption
Description: Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days
Study NCT04749017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
Study NCT06233019 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart
Description: Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
Study NCT04481373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes.
Study NCT04481373 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
Study NCT05311137 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
Study NCT06441539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bingo® Paclitaxel coated balloon
Description: Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon
Study NCT06441539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience® Alpine Everolimus Eluting Coronary Stent System
Description: Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
Study NCT04825041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patency test
Description: Successive flow test, bubble flow test and peristalsis test
Study NCT06336551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for insomnia (ACT-I)
Description: During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
Study NCT05565300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling exercise
Description: 30 minutes of cycling (90 rpm).
Study NCT05565300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: 30 minutes of cycling (90 rpm).
Study NCT05565300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: 30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
Study NCT05696171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant manual insertion
Description: Manual insertion of the cochlear implant into the round window during the surgery
Study NCT05717270 — intervention group
Intervention type: PROCEDURE
Intervention: Two-layered suture repair
Description: The ruptured Achilles tendon will be sutured in two-layer.
Study NCT06504147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radspherin
Description: Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
Study NCT06557330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
Study NCT06557330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Study NCT04265950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study NCT04265950 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study NCT04873362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
Study NCT04873362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
Study NCT04873362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
Study NCT04873362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
Study NCT04873362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
Study NCT04873362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
Study NCT06118892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MISHA Knee System
Description: The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
Study NCT05674851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: collection of MRI scans for mathematical model development
Study NCT04955821 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS diagnose of VAP
Description: This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
Study NCT04825366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring device
Description: Participants will have to wear their continuous glucose monitoring device throughout the study.
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gold method
Description: The Gold method will be used to assess impaired awareness of hypoglycemia
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clarke questionnaire
Description: The Clarke questionnaire will be used to assess impaired awarness of hypoglycemia
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Edinburgh Hypoglycemia Symptom Scale
Description: The Edinburgh Hypoglycemia Symptom Scale will be used to assess symptoms of hypoglycemia
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BAPAD questionnaire
Description: The BArriers to Physical Activity in type 1 Diabetes (BAPAD) questionnaire will be used to assess barriers of physical activity
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia Fear Survey II
Description: The Hypoglycemia Fear Survey II will be used to assess fear of hypoglycemia
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity questionnaire
Description: The International Physical Activity Questionnaire will be used to assess physical activity practice
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Well-being
Description: The WHO-5 well-being index will be used to assess well-being.
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment satisfaction
Description: The Diabetes Treatment Satisfaction Questionnaire will be used to assess treatment satisfaction.
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia diary
Description: Participants will be asked to record in a diary treatments for hypoglycemic events
Study NCT04825366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Piezo RxD
Description: Participants will be asked to wear a pedometer throughout the study
Study NCT04825366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate monitor
Description: During training sessions, participants will be asked to wear a heart rate monitor
Study NCT04825366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise diary
Description: Before each training session, participants will be asked to note in a diary their glucose levels, if they have taken a snack or not and if insulin was administered. After each training session, participants will be asked to note that same information. In addition, they will be asked to note their bedtime blood glucose, if they have taken a bedtime snack and if adjustment to insulin doses was made.
Study NCT04635267 — intervention group
Intervention type: OTHER
Intervention: Prone position in patients with ARDS
Description: Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
Study NCT05983107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
Study NCT05983107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）
Study NCT05983107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
Study NCT05983107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression(OFS)
Description: Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
Study NCT05744193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exempt Infant Formula
Description: Liquid human milk fortifier to be added to human milk daily
Study NCT05744193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exempt Infant Formula
Description: Liquid human milk fortifier to be added to human milk daily
Study NCT05696171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cochlear implant robotized insertion
Description: Robotic insertion of the cochlear implant into the round window during the surgery
Study NCT04817072 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (20mL) for pro-inflammatory cytokines assay
Study NCT06259279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity high impact exercise intervention
Description: Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes.
Study NCT05129254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Thulium laser
Description: For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
Study NCT05129254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma Injection
Description: Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
Study NCT05727202 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Description: A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
Study NCT05129254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma Topical Application
Description: Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
Study NCT05540652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Queer Resilience (MBQR)
Description: Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community.
Study NCT04104555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birthday card
Description: Birthday card sent to participants in the post
Study NCT04104555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated orthoses
Description: Prefabricated insole
Study NCT04104555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Signposting to multimedia
Description: Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
Study NCT04104555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual supportive care - exercises and footwear advice (the comparator)
Description: Active comparator
Study NCT06336213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Description: If a patient meets dual criteria (presepsin > 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
Study NCT04817189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEPA (300mg netupitant/0.5mg palonosetron)
Description: Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.